💨 Abstract

Cullinan Therapeutics (CGEM) reported a $48.5 million loss, or 74 cents per share, in Q1 2025, surpassing Wall Street's expectations of a 78 cents per share loss. The biotech company’s shares have dropped 37% since the start of the year and 74% over the past 12 months. The company is based in Cambridge, Massachusetts.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖